Resources

In-the-Know With Verastem Oncology

Access the latest posters, presentations and publications from Verastem Oncology below:

Feature resources

Animation Video Demonstrating How VS-6766 and Novel Combinations Better Control RAS Pathway and Parallel Pathway Signaling

Jonathan Pachter, PhD, Chief Scientific Officer

Verastem Oncology 2021

A Scientific Overview of VS-6766: An Investigational Backbone of Therapy in RAS-Driven Cancers

Jonathan Pachter, PhD, Chief Scientific Officer; Stephanie Lustgarten, PhD, Vice President, Biometrics; Silvia Coma, Director, Preclinical Research & Medical Affairs Operations

Verastem Oncology 2021

VS-6766

Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

S. Banerjee, R. Grochot, R. Shinde, J. Lima, M. Krebs, R. Rahman, M. Little, N. Tunariu, A. Curcean, H. Badham, M. Mahmud, A. Turner, M. Parmar, C. Yap, A. Minchom, J. Lopez, J. de Bono, U. Banerji.

2021 ESMO Congress

Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12V or G12C Variants

Jonathan Pachter, PhD, Chief Scientific Officer

NSCLC Drug Development Summit – July 14, 2021

Searching for Treatments for Non-G12C-KRAS Mutant Cancers

Christina Guo & Udai Banerji

British Journal of Cancer (2021) - April 15, 2021

FRAME: A Phase I Trial of the Combination of the Dual RAF/MEK Inhibitor VS-6766 and the FAK Inhibitor Defactinib; Evaluation of Efficacy in KRAS Mutated NSCLC

Matthew G. Krebs, Rajiv Shinde, Rozana Abdul Rahman, Rafael Grochot, Martin Little, Jenny King, Mark Van De Velde, Joseph Kitchin, Mona Parmar, Alison Turner, Muneeb Mahmud, Christina Yap, Nina Tunariu, Juanita Lopez, Johann S. de Bono, Udai Banerji, Anna Minchom

AACR Virtual Annual Meeting – April 10-15, 2021 & May 17-21, 2021

Dual RAF/MEK Inhibitor VS-6766 Enhances Anti-Tumor Efficacy of KRAS G12C Inhibitors Through a Vertical Pathway Inhibition Strategy

Silvia Coma, Sanjib Chowdhury, Jonathan A Pachter

AACR Virtual Annual Meeting – April 10-15, 2021 & May 17-21, 2021

Synergistic Antitumor Efficacy of the Dual RAF/MEK Inhibitor VS-6766 With FAK Inhibition for Treatment of RAS-Dependent Solid Tumors

Silvia Coma, Monica Musteanu, Justine S. Paradis, J. Silvio Gutkind, Mariano Barbacid, Jonathan A. Pachter

AACR Virtual Annual Meeting – April 10-15, 2021 & May 17-21, 2021

Synergistic Combinations With the Novel Dual RAF/MEK Inhibitor VS-6766: Establishing VS-6766 as the Backbone of Therapy for RAS-Driven Cancers

Silvia Coma, Sanjib Chowdhury, Jonathan A. Pachter

RAS-Targeted Drug Discovery Summit – February 23-25, 2021

Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Simone Lubrano, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind

Clinical Cancer Research. 2021 February 10; DOI: 10.1158/1078-0432.CCR-20-3363

Intermittent Schedules of the Oral RAF/MEK Inhibitor CH5126766/VS-6766 in Patients With RAS/RAF-Mutant Solid Tumours and Multiple Myeloma: a Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, Samuel J Harris, Irene Moreno Candilejo, Priya Sriskandarajah, Wen Xu, Mariana Scaranti, Anastasia Constantinidou, Jenny King, Mona Parmar, Alison J Turner, Suzanne Carreira, Ruth Riisnaes, Laura Finneran, Emma Hall, Yuji Ishikawa, Kiyohiko Nakai, Nina Tunariu, Bristi Basu, Martin Kaiser, Juanita Suzanne Lopez, Anna Minchom, Johann S de Bono, Udai Banerji

Lancet Oncology. 2020 October 28; 21 (11): 1478-1488. DOI: 10.1016/S1470-2045(20)30464-2

Synergistic Combinations With the Dual RAF/MEK Inhibitor VS-6766 to Overcome Resistance Mechanisms

Jonathan Pachter, PhD

RAS-Targeted Drug Development - September 16, 2020

Clinical Combinations: Dual RAF-MEK & FAK Inhibition for the Treatment of KRAS Mutant Cancers With a Focus on Low-Grade Serous Ovarian Cancer

Dr. Udai Banerji

RAS-Targeted Drug Development - September 16, 2020

Phase I Study of the Combination of a RAF/MEK Inhibitor CH5126766 and FAK Inhibitor Defactinib in an Intermittent Dosing Schedule With Expansions in KRAS Mutant Cancers

Rajiv Shinde, Angelika Terbuch, Martin Little, Reece Caldwell, Roopa Kurup, Ruth Riisnaes, Mateus Crespo, Ruth Ruddle, Bora Gurel, Adam Stewart, Jenny King, Mona Parmar, Alison Turner, Florence Raynaud, Muneeb Mahmud, Christina Yap, Jonathan A. Pachter, Gordon B. Mills, Anna Minchom, Juanita Lopez, Susana N. Banerjee, Johann S. de Bono, Matthew Krebs, Udai Banerji

AACR Session I April 24-29, 2020 & Session II June 22-24, 2020

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Piro Lito, Anna Saborowski, Jingyin Yue, Martha Solomon, Eric Joseph, Sunyana Gadal, Michael Saborowski, Edward Kastenhuber, Christof Fellmann, Kazuhiro Ohara, Kenji Morikami, Takaaki Miura, Christine Lukacs, Nobuya Ishii, Scott Lowe, and Neal Rosen

Cancer Cell. 2014 May 12; 25(5): 697–710. doi:10.1016/j.ccr.2014.03.011

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766 (VS-6766), That Suppresses Feedback Reactivation of RAF Activity

Nobuya Ishii, Naoki Harada, Eric W. Joseph, Kazuhiro Ohara, Takaaki Miura, Hiroshi Sakamoto, Yutaka Matsuda, Yasushi Tomii, Yukako Tachibana-Kondo, Hitoshi Iikura, Toshihiro Aoki, Nobuo Shimma, Mikio Arisawa, Yoshihiro Sowa, Poulikos I. Poulikakos, Neal Rosen, Yuko Aoki, and Toshiyuki Sakai

Cancer Res. 2013 July 1; 73(13): 4050–4060. doi:10.1158/0008-5472.CAN-12-3937

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual RAF/MEK Inhibitor in Patients With Solid Tumors

Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen and Jean-Charles Soria

Clin Cancer Res. 2012 September 1; (18) (17): 4806-4819. doi: 10.1158/1078-0432.CCR-12-0742

CRAF, but Not BRAF, Is Essential for Development of KRAS Oncogene-Driven Non-Small Cell Lung Carcinoma

Rafael B. Blasco, Sarah Francoz, David Santamaría, Marta Cañamero, Pierre Dubus, Jean Charron, Manuela Baccarini, and Mariano Barbacid

Cancer Cell. 2011 May 17; 19(5): 652–663. doi:10.1016/j.ccr.2011.04.002

Defactinib

Targeting FAK in Anticancer Combination Therapies

John C. Dawson, Alan Serrels, Dwayne G. Stupack, David D. Schlaepfer & Margaret C. Frame

Nature Reviews Cancer. 2021 March 17; doi.org/10.1038/s41568-021-00340-6

Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer: Experiences of Pancreatic Ductal Adenocarcinoma (PDAC) Patients

Andrea Wang-Gillam, Robert McWilliams, A. Craig Lockhart, Benjamin R. Tan Jr., Rama Suresh, Kian-Huat Lim, Katrina S. Pedersen, Nikolaos Trikalinos, Olivia Aranha, Haeseong Park, Lee Ratner, Nicholas Boice, David G DeNardo.

AACR Session I April 24-29, 2020 & Session II June 22-24, 2020

Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer

David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier P. Scaglioni, Song Zhang, Marilyn Li, David T. Weaver, Louis Vaikus, Mitchell Keegan, Joanna C. Horobin, and Timothy F. Burns

Lung Cancer. 2020 Jan; 139: 60–67. doi: 10.1016/j.lungcan.2019.10.033

FAK Activity Sustains Intrinsic and Acquired Ovarian Cancer Resistance to Platinum Chemotherapy

Carlos J Diaz Osterman, Duygu Ozmadenci, Elizabeth G Kleinschmidt, Kristin N Taylor, Allison M Barrie, Shulin Jiang, Lisa M Bean, Florian J Sulzmaier, Christine Jean, Isabelle Tancioni, Kristen Anderson, Sean Uryu, Edward A Cordasco, Jian Li, Xiao Lei Chen, Guo Fu, Marjaana Ojalill, Pekka Rappu, Jyrki Heino, Adam M Mark, Guorong Xu, Kathleen M Fisch, Vihren N Kolev, David T Weaver, Jonathan A Pachter, Balázs Győrffy, Michael T McHale, Denise C Connolly, Alfredo Molinolo, Dwayne G Stupack, and David D Schlaepfer

eLife. 2019; 8: e47327. Published online 2019 Sep 3. doi: 10.7554/eLife.47327

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

Alan Serrels, Tom Lund, Bryan Serrels, Adam Byron, Rhoanne C. McPherson, Alexander von Kriegsheim, Laura Go´ mez-Cuadrado, Marta Canel, Morwenna Muir, Jennifer E. Ring, Eleni Maniati, Andrew H. Sims, Jonathan A. Pachter, Valerie G. Brunton, Nick Gilbert, Stephen M. Anderton, Robert J.B. Nibbs, and Margaret C. Frame

Cell. 2016 September 24; 163(1): 160-173. doi: 10.1016/j.cell.2015.09.001

Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

Hong Jiang, Samarth Hegde, Brett L. Knolhoff, Yu Zhu1, John M. Herndon, Melissa A. Meyer, Timothy M. Nywening, William G. Hawkins, Irina M. Shapiro, David T. Weaver, Jonathan A. Pachter, Andrea Wang-Gillam, and David G. DeNardo

Nat Med. 2016 August; 22(8): 851–860. doi:10.1038/nm.4123

A Phase I Study of VS-6063, a Second-Generation Focal Adhesion Kinase Inhibitor, in Patients With Advanced Solid Tumors

Suzanne F Jones, Lillian L Siu, Johanna C Bendell, James M Cleary, Albiruni R A Razak, Jeffrey R Infante, Shuchi S Pandya, Philippe L Bedard, Kristen J Pierce, Brett Houk, W Gregory Roberts, S Martin Shreeve, Geoffrey I Shapiro

Invest New Drugs. 2015 Oct;33(5):1100-7. doi: 10.1007/s10637-015-0282-y